BioCentury
ARTICLE | Company News

FDA grants Novartis priority review for Zelmac

April 12, 2000 7:00 AM UTC

NOVN received priority review designation for Zelmac tegaserod to treat multiple symptoms of irritable bowel syndrome. ...